(Q37738765)

22 August 2017

1 reference

title

CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance (English)

1 reference

22 August 2017

1 reference

2

Vered Stearns

1 reference

22 August 2017

Michaela J Higgins

1

1 reference

22 August 2017

1 January 2010

1 reference

22 August 2017

Current Oncology Reports

1 reference

22 August 2017

12

1 reference

22 August 2017

1

1 reference

22 August 2017

7-15

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-009-0076-5

22 August 2017

0 references

cites work

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-009-0076-5

Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-009-0076-5

Welcome to the genomic era.

21 January 2018

1 reference

12 December 2020

A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma

1 reference

12 December 2020

Cytochrome P450 pharmacogenetics and cancer.

1 reference

12 December 2020

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

1 reference

12 December 2020

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

1 reference

12 December 2020

Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer

1 reference

12 December 2020

Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells

1 reference

12 December 2020

Inheritance and drug response

1 reference

12 December 2020

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

1 reference

12 December 2020

Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy

1 reference

12 December 2020

Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases

1 reference

12 December 2020

CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

12 December 2020

Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.

1 reference

12 December 2020

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

1 reference

12 December 2020

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells

1 reference

12 December 2020

Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.

1 reference

12 December 2020

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

1 reference

12 December 2020

Cancer statistics, 2009

1 reference

12 December 2020

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients

1 reference

12 December 2020

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment

1 reference

12 December 2020

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis

1 reference

12 December 2020

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

1 reference

12 December 2020

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

1 reference

12 December 2020

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

1 reference

12 December 2020

An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer

1 reference

12 December 2020

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy

1 reference

12 December 2020

Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans

1 reference

12 December 2020

No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications

1 reference

12 December 2020

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update

1 reference

12 December 2020

Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer

1 reference

12 December 2020

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis

1 reference

12 December 2020

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

1 reference

12 December 2020

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

1 reference

12 December 2020

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

12 December 2020

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

1 reference

12 December 2020

Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen Trial

1 reference

12 December 2020

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

1 reference

12 December 2020

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

1 reference

12 December 2020

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group

1 reference

12 December 2020

Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

1 reference

12 December 2020

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

1 reference

12 December 2020

Genotype-guided tamoxifen therapy: time to pause for reflection?

1 reference

12 December 2020

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

12 December 2020

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes

1 reference

12 December 2020

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

1 reference

12 December 2020

Metabolic gene polymorphism frequencies in control populations

1 reference

12 December 2020

Pharmacogenomics--drug disposition, drug targets, and side effects

1 reference

12 December 2020

Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.

1 reference

12 December 2020

Human aromatase: gene resequencing and functional genomics

1 reference

12 December 2020

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

12 December 2020

10.1007/S11912-009-0076-5

Identifiers

DOI

1 reference

release_ji3qmmcxszdwxevkia3zhh7fqa

22 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ji3qmmcxszdwxevkia3zhh7fqa

24 November 2022

mapped directly with Wikidata item

PubMed ID

20425602

1 reference

PubMed ID

20425602